Core Insights - Aprea Therapeutics announced the first unconfirmed partial response (uPR) in a patient from its Phase 1 ACESOT-1051 study, indicating early clinical activity of APR-1051 in treating advanced solid tumors [1][2] Group 1: Clinical Trial Results - The uPR was observed in a patient with PPP2R1A-mutated uterine serous carcinoma, showing a 50% reduction in target lesion size and a decrease in CA-125 levels from 732 to 70 U/mL after treatment with APR-1051 at the 150 mg dose level [2][7] - Earlier cohorts in the ACESOT-1051 study reported stable disease in multiple patients, including a 5% reduction in tumor burden in a patient with HPV-positive head and neck squamous cell carcinoma and a 15% reduction in a patient with FBXW7-mutated colon cancer [3] - The ongoing dose-escalation study is currently enrolling patients in the 220 mg cohort, with plans to increase enrollment of HPV-positive patients [4][6] Group 2: Drug Mechanism and Strategy - APR-1051 is a small-molecule inhibitor of WEE1 kinase, designed to exploit cancer-specific vulnerabilities while minimizing damage to healthy cells [8][9] - The company aims to target cancers with specific genomic alterations, including mutations in PPP2R1A, FBXW7, CCNE1, TP53, and KRAS, reinforcing the potential of APR-1051 as a differentiated treatment option [5] Group 3: Future Outlook - Aprea Therapeutics plans to provide additional updates in the first half of 2026 and complete dose escalation later in the year, indicating ongoing commitment to the development of APR-1051 [5]

Core Viewpoint - Aprea Therapeutics has announced a private placement of common stock and warrants, aiming to raise approximately $5.6 million to support its ongoing clinical studies and general corporate purposes [1][2][3] Group 1: Offering Details - Aprea will sell a total of 6,288,857 shares of common stock (or pre-funded warrants) along with warrants to purchase an equal number of shares, at an effective offering price of $0.89 per share [1][2] - The warrants will have an exercise price of $0.765 per share, exercisable immediately upon issuance, and will expire two years from the effectiveness date of the registration statement [1][2] Group 2: Use of Proceeds - The gross proceeds from the offering are estimated to be around $5.6 million before deducting fees and expenses, which will be used for general corporate purposes and research and development expenses [2] Group 3: Clinical Development Focus - The financing is intended to support the ongoing ACESOT-1 dose-escalation study of APR-1051, a WEE1 kinase inhibitor, with the goal of optimizing dosage and patient population [3] - The addition of more patients to the study is expected to enhance the dataset for safety and early efficacy, potentially leading to significant clinical milestones [3] Group 4: Company Overview - Aprea Therapeutics is focused on developing innovative cancer treatments that target specific vulnerabilities in cancer cells while minimizing harm to healthy cells [6] - The company's lead programs include APR-1051 and ATRN-119, both of which are in clinical development for solid tumor indications [7]

As filed with the Securities and Exchange Commission on January 28, 2026 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 APTEVO THERAPEUTICS INC. (Exact Name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Incorporation or Organization) (Primary Standard Industrial Classification Code Number) Delaware 2834 81-1567056 (I.R.S. Employer Identification Number) 2401 4th Avenue ...

“Cancer treatment comes at a cost.” Doctors say life-saving cancer care is creating a new challenge: managing treatment-related heart damage for a record number of survivors. https://t.co/vpYHq10Twf ...

Company Overview - Adagene Inc. (NASDAQ:ADAG) specializes in developing monoclonal antibody drugs for cancer treatment, currently trading at $2.49 with a target price of $1.67, indicating a potential downside of 33.08% [1][5] - Adicet Bio, Inc. (NASDAQ:ACET) focuses on gamma delta T cell therapies, trading at $8.44 with a discounted cash flow valuation of $7.15, reflecting a potential downside of 15.29% [2][5] Market Sentiment - The market sentiment towards both Adagene and Adicet Bio is cautious, as evidenced by the negative growth potential reflected in their stock prices [3][5] - Despite the innovative nature of their cancer treatment approaches, investment analysts remain wary due to inherent risks and uncertainties in the biotechnology sector [4][5] Industry Context - The biotechnology industry is characterized by high-risk, high-reward dynamics, with companies often facing challenges in clinical trials, regulatory approvals, and market adoption [4]

“Cancer treatment comes at a cost.” Doctors say life-saving cancer care is creating a new challenge: managing treatment-related heart damage for a record number of survivors. https://t.co/vpYHq10Twf ...

Core Insights - Corcept Therapeutics Incorporated (NASDAQ:CORT) is focused on developing medications that modulate cortisol effects to treat severe disorders, including oncologic conditions [1] - H.C. Wainwright upgraded CORT's stock to "Buy" and raised its price target from $90 to $105, with the stock priced at approximately $41.87 at the time of the announcement [1][5] Stock Performance - Following the upgrade, CORT's stock has seen a notable increase, currently priced at $41.30, reflecting a 13.74% increase with a change of $4.99 [3][5] - The stock has fluctuated between a low of $40.46 and a high of $52.84 during today's trading [3] - Over the past year, the stock reached a high of $117.33 and a low of $32.99 [3] Clinical Trial Results - The upgrade coincides with significant developments, particularly the successful results from the ROSELLA Phase 3 trial, which tested the combination of relacorilant and nab-paclitaxel for treating platinum-resistant ovarian cancer [2] - The trial demonstrated a 35% reduction in the risk of death for patients receiving the combination therapy [2][5] - The combination therapy was well-tolerated, with adverse events similar to those experienced with nab-paclitaxel monotherapy [4] Market Capitalization and Trading Volume - Corcept's market capitalization is approximately $4.34 billion, with a trading volume of 5,304,058 shares [4]

Core Viewpoint - Merck & Co., Inc. is making significant advancements in cancer treatment through its collaboration with Moderna, particularly with a promising cancer vaccine aimed at melanoma, which has shown a substantial reduction in relapse or death risk among patients [3][4][6]. Group 1: Company Overview - Merck & Co., Inc. is a global healthcare company known for its innovative research in oncology, vaccines, and infectious diseases [1]. - The company faces competition from major pharmaceutical players such as Pfizer and Johnson & Johnson [1]. Group 2: Stock Performance and Analyst Ratings - Cowen & Co. has maintained a "Hold" rating for Merck, with the stock currently priced at $108.83, reflecting a 1.93% decrease [2][5]. - TD Cowen has raised Merck's price target from $100 to $120, indicating optimism about the company's future performance [2][6]. - Merck's market capitalization is approximately $271.83 billion, with a trading volume of 10.72 million shares, suggesting active investor interest [5]. Group 3: Cancer Vaccine Study Results - Merck, in collaboration with Moderna, reported promising results from a cancer vaccine study, showing a 49% reduction in the risk of recurrence or death for melanoma patients [3][4][6]. - The combination of the experimental vaccine with Merck's Keytruda demonstrated sustained benefits over five years, highlighting its potential impact on serious skin cancer treatment [4][6].

Core Insights - Sana Biotechnology, Inc. focuses on developing ex vivo hypoimmune therapy and in vivo fusogen-based delivery systems to treat cancer and autoimmune diseases [1] Company Overview - The company is engaged in innovative biotechnological solutions aimed at addressing significant medical challenges in oncology and autoimmune disorders [1] Technology and Innovation - Sana's ex vivo platform is designed to enhance therapeutic efficacy by utilizing hypoimmune strategies, which may improve patient outcomes in complex diseases [1]

JP Morgan Healthcare Conference January 2026 NASDAQ GS ALXO This presentation concerns product candidates that are under clinical investigation, and which have not yet been approved for marketing by the U.S. Food and Drug Administration. These product candidates are currently limited by federal law to investigational use, and no representation is made as to their safety or effectiveness for the purposes for which they are being investigated. This presentation also contains estimates and other statistical da ...